Aim immunotech files provisional patent application for ampligen as an early-onset intranasal therapy that may also confer enhanced immunity to a wide range of respiratory viruses

Ocala, fla., sept. 27, 2021 (globe newswire) -- aim immunotech inc. (nyse american: aim) today announced the filing of a provisional patent application for ampligen as a potential early-onset intranasal therapy designed to enhance and expand infection-induced immunity, epitope spreading, cross-reactivity and cross-protection in patients exposed to a wide range of rna respiratory viruses, such as influenza, rhinoviruses and sars-cov-2, which causes the disease covid-19.
AIM Ratings Summary
AIM Quant Ranking